Medical Futures & Cipher Pharmaceuticals in Tramadol Deal

Medical Futures to gain a slice of Canadian tramadol market through deal with Cipher

Medical Futures, a Canada-based pharma company, has signed a pact for Cipher Pharmaceuticals to distribute Durela in Canada. Patent-protected Durela is a once-a-day formulation of tramadol for the treatment of moderate- to moderately-severe chronic pain in adults. It was approved by Health Canada in August and has immediate- and extended-release properties.

As for the particulars of the distribution deal, Cipher will receive an upfront payment from Medical Futures of C$300,000, and could also be eligible for future payments, dependant on net sales milestones. Also, Cipher will get its hands on a double-digit royalty on new sales. Cipher has further responsibily for product supply and manufacturing, which will be taken care of by its supplier, Galephar Pharmaceutical Research.

Medical Futures’ CEO, Colin Campbell, says he is excited to offer Durela in Canada, believing that the product “strengthens and demonstrates [Cipher’s] commitment to providing top tier solutions to the Canadian market”. It appears Cipher is equally delighted with the deal, as it provides valuable royalty revenue to the company. Cipher also recently shook hands on a US$5.5 million US distribution deal for Durela with Vertical Pharmaceuticals, with the former set to receive a payment of US$1 million on the first commercial sale of the product.

With sales of over US$60 million in 2010, the seemingly robust Canadian tramadol market looks like a sure thing for both parties. Medical Futures plans to launch Durela in the first quarter of 2012.

Thanks to Sophie Bracken for this article, Sophie edits Espicom’s business publication Drug Delivery Insight.

Related articles

• Flutiform Presents Good Safety Profile in Asthma Patients (medical-technologyblog.com)
• Drug Delivery Insight – Celtic leads the way in launch of Anglo-Russian pharma firm (medical-technologyblog.com)
• Canadian Generic Pharmaceutical Association and Apotex lose data protection challenge (thepharmaceutical-news.com)

Tagged with: Biotechnology and Pharmaceuticals • birmingham al • Birmingham Med tech companies • Business • Canada • Cipher Pharmaceuticals • cipher pharmaceuticals news • cipher pharmaceuticals tramadol • Clinical trial • current tramadol medical articles • Drug delivery • durela tramadol • Espicom Business Intelligence • Food and Drug Administration • futures pharmaceutical • med technology firms • MED-IN PHARMACEUTICALS • Medical Futures • medical technologist in pharmaceuticals • medical technologist sales • Medical Technology • Pharmaceutical • pharmaceutical research and medical technologist • Teva Pharmaceutical Industries • the+lately+medical+technology • United States

Filed under: Company News

Like this post? Subscribe to my RSS feed and get loads more!